

EGFL7 silencing inactivates the Notch signaling pathway; enhancing cell apoptosis and suppressing cell proliferation in human cutaneous melanoma

H. TANG, W. R. XIAO, Y. Y. LIAO, L. LI, X. XIAO, X. P. XU, H. FENG*

Department of Dermatology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, China

*Correspondence: Drfeng_hao@163.com

Received March 10, 2018 / Accepted July 4, 2018

Melanoma is the main cause of death in patients with skin cancer. While the pathogenesis of cutaneous melanoma is poorly understood, increasing evidence shows that epidermal growth factor (EGF) may be involved. Herein, we tested the hypothesis that down-regulation of EGFL7 inhibits development and progression of human cutaneous melanoma (CM). Initially, we performed immunohistochemical analysis of EGFL7 in 130 specimens and the findings indicated that EGFL7 was highly expressed in CM. The expressions of EGFL7 and Notch signaling pathway-related genes in CM were then measured by reverse transcription quantitative polymerase chain reaction (RT-qPCR) and Western blot assay. In order to assess biological functions of EGFL7 in CM we up-regulated or down-regulated endogenous EGFL7 using EGFL7-OE or shRNA against EGFL7 in the A375 CM cell line. To better understand the pivotal role of Notch signaling pathway in CM, we blocked this pathway in A375 cells by inhibitor treatment. Finally, tumor xenograft in nude mice was performed to test the *in vivo* tumorigenesis of the transfected A375 cells. While EGFL7 activated the Notch signaling pathway in CM, gain- and loss-of-function studies established that decreased EGFL7 inhibited cell proliferation and promoted apoptosis in A375 cells. Moreover, down-regulated EGFL7 suppressed *in vivo* tumorigenesis. Most importantly, we determined that down-regulating EGFL7 inhibited CM development by suppressing the Notch signaling pathway. The combined findings define potential roles of decreased EGFL7 as inhibitors of CM development by suppressing the Notch signaling pathway, and EGFL7 may therefore be a novel therapeutic target in cutaneous melanoma patients.

Key words: epidermal growth factor-like domain 7, Notch signaling pathway, proliferation, apoptosis, human cutaneous melanoma

Human cutaneous melanoma (CM) is the most malignant skin tumor and a leading cause of skin cancer deaths [1]. It is also one of the most aggressive forms of human cancer and considerable phenotypic plasticity is exhibited by melanoma cells [2]. As phenotypically and molecularly heterogeneous diseases, cutaneous, uveal, acral and mucosal melanomas have different clinical courses, involving various mutational profiles and possessing different risk factors [3]. Importantly, approximately one third of women diagnosed with melanoma are of childbearing age [4]. In both the initiation and progression of CM, a recent study indicated that ultraviolet radiation is a major factor inducing DNA mutation [5]. For the treatment of advanced malignant melanoma, an anti-CTLA-4 IgG1 monoclonal antibody (also called ipilimumab) was approved by the United States in 2011 and in Japan in 2015 [6]. Although overall survival of melanoma patients has been improved by new treatments, prognosis

remains poor [7] and cutaneous melanoma metastases cause treatment difficulty [8].

Recently, polymorphisms of epidermal growth factor (EGF) G1380A, bFGF C754G and VEGF T460C have been correlated with malignant melanoma susceptibility and prognosis [9]. An EGF-based approach was therefore adopted to investigate related genes involved in CM occurrence, and this may well aid future intervention and treatment strategies.

EGF is a member of the epidermal growth factor superfamily and acts as a potential mitogenic factor with important roles in different cell type growth, proliferation and differentiation [10]. Moreover, EGFL7 has recently been considered an important factor in vascular development and in carcinogenesis associated with vascular tube formation [11, 12]. The vascular development of melanoma tumors is closely related to tumor angiogenesis [13], and the Notch signaling pathway

is an important factor there because its activation can be triggered by Dll4 disruption [14].

While the Notch signaling pathway has only a small number of core signaling components and simple molecular design, it affects cell differentiation decisions across a wide spectrum of metazoan species and a broad range of cell types [15]. However, secreted EGFL7 has been reported to bind to a Notch region involved in ligand mediated receptor activation and to be an antagonist in Notch signaling [16]. This study therefore investigates the association between EGFL7 and the Notch signaling pathway in cutaneous melanoma.

Patients and methods

Ethics statement. The experiment was conducted in strict accordance with Guidance on Laboratory Animal Experiment Process (NSC398, 2006) released by Ministry of Science and Technology of the People's Republic of China and Guide for the Care and Use of Laboratory Animals (NIH publication number 85-23, revised 1996). Efforts were made to minimize both animal suffering and the number of animals used. This study protocol was approved by the Institutional Review Board of our hospital (No. 20130701) and written informed consent obtained from all patients.

Subjects and specimen collection. From July 2012 to May 2017, 65 patients diagnosed with malignant CM by histological examination and who underwent surgical resection in our hospital pathology department were enrolled in this study. A total of 65 resected CM tissues were collected. The patients comprised 36 males and 29 females, aged from 29 to 82; 46 > 65 and 19 ≤ 65. The inclusion criteria were as follows: 1) patients had complete clinical-pathological data; 2) no chemotherapy, radiotherapy or other new treatment was received before the operation and 3) the patient had no other primary tumors. The NSCLC stage was made according to the TNM classification criteria with 16 stage I, 25 stage II-a and 24 stage II-b (no lymph node metastases in stage I, regional lymph node metastases but without distant metastasis in stage II). We then collected 65 specimens from para-cancerous tissues as controls.

Hematoxylin-eosin (HE) staining. Fixed specimens were de-waxed using terephthalaldehyde (Wuhan Kangdeli Chemical, China). The slices were rinsed in ethanol, different concentrations of ethanol and then distilled water, stained by hematoxylin (Baiaolaibo Technology, China) for about 4 min and rinsed until the cell nuclei were stained blue. Afterwards, they were stained by rinsing in eosin, 95% ethanol and absolute ethanol, followed by repeat process. The stained specimens were immersed in xylene, sealed and labeled. Finally, the specimens were analyzed by ordinary optical microscope (Ausiwei Optical Instrument, China). The experiment was repeated three times.

Immunohistochemical analysis. Tissue mass was fixed by 10% formalin, embedded in paraffin and sliced (about 4 mm). The slices were rinsed in xylene (20 min) and xylene

II (20 min) for de-waxing, dehydrated by gradient alcohol (100%, 90%, 80% and 70%). High-pressure antigen retrieval was conducted as follows: immersing in citrate buffer at 95 °C, cooling and rinsing in phosphate buffered solution (PBS) for three times (3 min each). For suppressing the endogenous peroxidase activity, 50 μl of 3% hydrogen peroxide was added. Successively, all slices were added with 50 μl blocking serum for 30 min and cultured with rabbit anti-human EGFL7 polyclonal antibody (ab115786, 1:100 dilution, Abcam, UK) in wet boxes in a refrigerator at 4 °C overnight. Slices were then re-warmed at 37 °C for 45 min and goat anti-rabbit IgG labeled by biotin was added to each slice for 30 min at 37 °C. Following adding with chain enzyme avidin, the specimens were colored by diaminobenzidine (DAB) and counter-stained with hematoxylin. Excess xylene was removed and neutral gum was added. The slices were then placed on slides with coverslips and were observed under a microscope (DMM-300D, Shanghai Cai Kang Optical Instrument, China). The result of the immunohistochemical analysis was confirmed positive when brown particles appeared in the cytoplasm. Five non-repetitive areas were randomly selected on each slice under the microscope, and about 200 cells were chosen in each area. The proportion of positive cells was regarded as the positive expression rate.

RNA extraction and reverse transcription quantitative polymerase chain reaction (RT-qPCR). Total RNA was extracted using Trizol reagent (Thermo Fisher Scientific, USA) and 5 μg was used. The cDNA was synthesized by reverse transcription kit (Abbiotec, USA) according to instructions. All target genes were amplified in PCR using a 25-μl system: 300 ng cDNA, 1 × PCR buffer, 200 μmol/l dNTPs, forward and reverse primers of 80 pmol/l each and 0.5 U Taq enzyme (Yuanye Biological Technology, China). Reaction condition of RT-qPCR consisted of pre-denaturation at 95 °C for 5 min, followed by 30 cycles of denaturation at 95 °C for 30 s, annealing at 60 °C for 30 s and extension at 70 °C for 30 s. U6 was utilized as the internal reference. The primer sequences are shown in Table 1. The $2^{-\Delta\Delta Ct}$ referred to the relative expressions of target genes, with the formula as follows: $\Delta\Delta Ct = \Delta Ct_{\text{experimental group}} - \Delta Ct_{\text{control group}}$, $\Delta Ct = Ct_{\text{miRNA}} - Ct_{\text{U6}}$. Ct is the logarithmic increase in the number of amplification cycles required for the real time fluorescence intensity of the reaction to reach a set threshold. The experiment was conducted three times. This part is also suitable for cell experiments.

Western blot assay. Total proteins were measured according to the instructions of Radio Immunoprecipitation Assay (RIPA) kit (Suolaibao Scientific Technology, China). The transfected cells were rinsed three times in cold PBS, added with protein lysate (60% RIPA + 39% sodium dodecyl sulfate (SDS) + 1% protease inhibitor) into cell flask. After being collected in an Ependorf (EP) tube, cells were then lysed on ice for 30 min, centrifuged at 12,000 rpm and 4 °C for 30 min, followed by the supernatant being collected, and then placed in an ice bottle. The bicinchoninic acid (BCA)

protein assay kit (Shanghai Jining, China) tested protein concentration. The SDS-polyacrylamide gel electrophoresis (SDS-PAGE) kit was applied to prepare 10% separation gel and 5% stacking gel for the electrophoretic separation of protein. Then, the protein specimens were transferred onto nitrocellulose (NC) membranes and sealed with 5% bovine serum albumin (BSA) at room temperature for an hour. Subsequently, the diluted rabbit anti-mouse polyclonal antibodies purchased from Abcam; EGFL7 (ab102796, 1:500), Notch1 (ab52627, 1:1000), Hes1 (ab71559, 1:200), Bcl-2 (ab32124, 1:1000), Bax (ab32503, 1:1000) and HEY1 (ab154077, 1:500) were added and incubated overnight at 4 C. The specimens were then rinsed 3 times (10 min each) with tris buffered saline tween (TBST). Skim milk (5%) diluted secondary IgG/FITC polyclonal antibody. Specimens were then incubated for an hour and rinsed three times with TBST. Eikonogen (Shanghai Yingdian Detection Equipment, China) and Bio-rad gel imaging system (MG8600, Beijing Thmorgan Biotechnology, China) were employed for development. IPP7.0 software (Media Cybernetics, Singapore) was used for quantitative analysis. The gray value ratio of EGFL7, Notch1, Hes1, Bcl-2 and Bax bands to band of internal reference of β -actin was considered relative protein expression. The experiment was repeated three times.

Plasmid construction. The shRNA sequences were designed according to the sequence of S-phase kinase-associated protein 2 (SKP2) reported by Genbank. This identified the target sequence in accordance with design principles. BLAST software determined the homology of other non-related genes. The oligonucleotide chain that could encode siRNA was designed based on the requirements of the Pg-PU6/Neo carrier. Unrelated shRNA sequence was synthesized by oligonucleotide fragments provided by Shanghai SANGON Biological Engineering Technology and Services. Carriers (ER0052 & ER0271, Kebai Biotechnology, China) and pSIREN (HAB 2-9, Huao Technology, China) linearized by Bam HI and Eco RI were inserted. After annealing through the construction of recombinant plasmid pSI-REN/S and pSIREN/CN, the ampicillin resistant colonies of bacteria were chosen in transformed Escherichia coli DH5 α , then amplified and cultured. Plasmids were prepared rapidly in small number and they underwent nucleic acid sequencing and identification to select clones with correct sequence for amplification and culture. The sequence with best silencing effect was used for subsequent cell experiments. The sequences of shRNA are shown in Table 2.

Cell culture, grouping and transfection. Human melanoma cell line A375 purchased from Shanghai Institute of cell biology of Chinese Academy of Sciences was incubated in Dulbecco's Modified Eagles Medium (DMEM) supplied with 10% fetal bovine serum (FBS) at 37°C and 5% CO₂. Cells were divided into blank, negative control (NC), EGFL7-OE (cells transfected with overexpressed EGFL7), EGFL7-shRNA1, DAPT (a Notch inhibitor) and EGFL7-shRNA1 + DAPT groups. Cells in the logarithmic growth

Table 1. Primer sequences for RT-qPCR.

Gene	Sequence (5' - 3')
EGFL7	Forward: TGAATGCAGTGCTAGGAGGG
	Reverse: GCACACAGAGTGTACCGTCT
Notch1	Forward: CGGGCGACGTCACCC
	Reverse: TCGTCGATATTTTCCTCACAGTTC
Hes1	Forward: TGGAAATGACAGTGAAGCACCT
	Reverse: GTTCATGCACTCGCTGAAGC
Bcl-2	Forward: ATGTGTGTGGAGAGCGTCAACC
	Reverse: TGAGCAGAGTCTTCAGAGACAGCC
Bax	Forward: GAGGATGATTGCCGCCGTGGACA
	Reverse: GGTGGGG GAGGAGGCTTGAGG
HEY1	Forward: CGAGGTGGAGAAGGAGAGTG
	Reverse: CTGGGTACCAGCCTTCTCAG
β -actin	Forward: GCCCAGAGCAAGAGAGGCAT
	Reverse: GGCCATCTCTTGCTCGAAGT

Notes: RT-qPCR: reverse transcription quantitative polymerase chain reaction; EGFL7: epidermal growth factor-like domain 7; HEY1: hairy/enhancer-of-split related with YRPW motif protein 1; β -actin: beta-actin.

Table 2. The shRNA sequences.

Gene	Sequence
EGFL7-shRNA1	GGGCATCTGAGCCTTTCATCA
EGFL7-shRNA2	GCCTAAGGGAAGTGCATTTAT
EGFL7-shRNA3	GCTCCACAAGGCTTCTCAAG
NC-shRNA	ACTACCGTTGTTATAGGTG

Note: EGFL7: epidermal growth factor-like domain 7; shRNA: short hair-pin RNA; NC: negative control

phase were inoculated in a 6-well plate. When cells grew to a density of 70%, transfection was conducted in accordance with the instructions of Lipofectamine 2000 kit (Invitrogen, USA). 100 pmol EGFL7-OE, EGFL7-shRNA1, DAPT, EGFL7-shRNA1 + DAPT, blank and NC was then diluted with 250 μ l of serum-free Opti-MEM (Gibco, USA) to a final concentration of 50 nM cells, mixed, and incubated at room temperature for 5 minutes. The Lipofectamine 2000 (5 μ l) was diluted with 250 μ l serum-free Opti-MEM and incubated for 5 min at room temperature. The above two were mixed and incubated at room temperature for 20 min. Following incubation at 37°C and 5% CO₂ and culturing for 6–8 h, the cells were further cultured in complete culture medium for 24–48 h for following experiments.

3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) assay. After reaching about 80% confluence, cells were washed twice with PBS, treated with 0.25% trypsin and made into single cell suspension, followed by cell counting. Cells were then seeded in a 96-well plate with a density of $3 \times 10^3 - 6 \times 10^3$ cells/well (200 μ l). Six replicates were prepared with 200 μ l per well. The medium was replaced by medium contain 10% MTT solution (5 mg/ml,

Guduo Biotechnology, China) at 24, 48 and 72 h for further 4-h culture. With the MTT solution aspirated, each well was added with 100 μ l of DMSO and shaken gently for 10 min in order to dissolve the formazan crystals formed by living cells. The optical density (OD) at 490 nm was measured by microplate reader for cell viability. Each experiment was repeated three times. Finally, the cell growth curve was drawn based on time points as abscissa and OD values as ordinate.

Flow cytometry. After transfection for 48 h, 0.25% trypsin treated collected cells. Cells were adjusted to a density of 1×10^6 /ml and 100 μ l cell suspensions were centrifuged at 1,500 rpm. The supernatant was discarded. The cells were collected, and 1 ml cells were added with 2 ml PBS, followed by centrifugation. With the supernatant discarded, cold ethanol (volume fraction of 70%) was added to fix cells at 4°C overnight. Cells were washed twice by PBS the following day, and we collected 100 μ l cell suspension (no less than 10^6 cells/ml) and used 1 ml propidium iodide (PI) solution (50 mg/l) containing RNAase to stain cells. After avoiding light for 30 min, cells were filtered by 300-mesh nylon net. Flow cytometry recorded the wavelength of the red fluorescence at 488 nm to detect the cell cycle.

Annexin V-FITC/PI double staining then detected cell apoptosis using the same process as in cell cycle detection. After incubation at 37°C with 5% CO₂ for 48 h, cells were collected and washed with PBS twice before being re-suspended in 20 μ l buffer. Annexin V-FITC of 10 μ l and PI of 5 μ l were mixed gently and reacted for 15 min in the dark at room temperature and 300 μ l buffer was added. Flow cytometry recorded the wavelength of the red fluorescence at 488 nm to detect cell apoptosis. (6HT, Wuhan Keliwa Trading, China)

Tumor xenograft in nude mice. A total of 30 male nude mice (age: 6–8 weeks; weight: 14–16 g) in pathogen free condition were purchased from Shanghai Silaike Experimental Animal Limited Company (Experimental Animal Center of Chinese Academy of Sciences in Shanghai). Mice were randomly classified into 6 groups with 5 in each group. Cells were inoculated after anesthesia, and cells in each group of logarithmic growth phase were re-suspended in 50% Matrigel (BD, Biosciences, US) to adjust the cell concentration to 1×10^7 cell/ml. Single cell suspension (5×10^6 cells) of 0.5 ml was injected subcutaneously in each mouse in the left axilla. After three-day free growth of tumor, the mice were treated with intraperitoneal injection of 5 mg/kg cisplatin every three days. The size of the tumor was determined by digital caliper and tumor volume was estimated using the formula volume = (length \times width²)/2. The changes in tumor growth rate were assessed by comparing the tumor volume on that treatment day with the tumor volume on the first treatment day; with a total of 21 days.

We then detected tumor microvascular density (MVD) in the transfected mice by immunohistochemical analysis. According to the method of Weidner et al., [17] for each stained section, 3 highest MVD areas were selected under

$\times 100$ microscope. The number of brown blood vessels was counted ($\times 200$). Three visual fields were counted in each specimen and the mean was calculated. Single red-stained endothelial cell or endothelial cell collection was numbered; regardless lumen formation. When the lumen was too large with thick muscularis or when there were more than 8 red cells in the lumen, these were not counted.

Statistical analysis. Data analysis was by SPSS 21.0 software (IBM Corp. Armonk, USA). Measurement data is presented as mean \pm standard deviation. The differences between two groups were analyzed using t-test, and statistical analysis in multiple groups was by one-way analysis of variance. A $p < 0.05$ indicated statistical significance.

Results

Pathological observation of CM and para-cancerous tissues. HE staining evaluated pathological changes, and results under light microscope showed that the tumor was composed of epithelioid cells, spindle cells and plasma cells (Figure 1). Most cells were arranged in nests, cords, acinar or were diffuse. Spindle tumor cells were mainly in bundle distribution. Nuclear fission was common and tumor nuclei were large with obvious eosinophilic nucleolus. Rich blood vessels could be seen between interstitial cells. Some had obvious hemorrhage and the boundary between tumor tissues and surrounding tissues was unclear. In contrast, the cell nucleolus of the para-cancerous tissues was clear and there was no cell aggregation.

EGFL7 is highly expressed in CM tissues. Since EGFL7 was confirmed to show abnormal expression in several cancers, we employed immunohistochemical analysis to detect the positive expression of EGFL7 in CM tissues (Figure 2). EGFL7 positive-expression was mainly in the cytoplasm and positive cells had yellow-brown granules. The positive expression rate of EGFL7 in the para-cancerous tissues was ($12.45 \pm 3.11\%$), and that in the CM tissues was ($89.32 \pm 5.31\%$); thus indicating EGFL7 expression was notably elevated in the CM tissues ($p < 0.05$).

EGFL7 and Notch related gene expression are elevated in CM tissues. To study the mechanisms and functions of EGFL7 and Notch related genes in CM tissues, their expressions were detected via RT-qPCR and Western blot assay (Figure 3). The results indicated that in contrast to the para-cancerous tissues, protein and mRNA expressions of EGFL7, Notch1, HES1, Bcl-2 and HEY1 in the CM tissues were obviously increased and Bax mRNA and protein expression decreased ($p < 0.05$).

Down-regulation of EGFL7 inhibited the Notch signaling pathway in transfected A375 cells. RT-qPCR and Western blot assay measured the A375 cell expression of EGFL7 and Notch related genes in each group after transfection (Figure 4). Results revealed no significant difference in the EGFL7 and Notch related gene expression between the blank and NC groups ($p > 0.05$). Compared with the blank and




Figure 1. HE staining of CM and para-cancerous human tissues under light microscope ($\times 200$). CM, cutaneous melanoma; HE, hematoxylin-eosin.




Figure 2. Immunohistochemical analysis indicated that EGFL7 expression was notably higher in the CM tissues than the paracancerous tissues. A) Staining of EGFL expression in CM and para-cancerous tissues; B) EGFL7 positive expression rate in CM and para-cancerous tissues. Measurement data is presented as mean \pm standard deviation. The differences between two groups were analyzed using t-test; *, $p < 0.05$ compared with the paracancerous tissues; para-cancerous tissues ($n=65$); CM, cutaneous melanoma ($n=65$); EGFL7, epidermal growth factor-like domain 7.

NC groups, the mRNA and protein expressions of EGFL7, Notch1, Hes1, Bcl-2 and HEY1 in the EGFL7-OE group were up-regulated while Bax mRNA and protein expression were down-regulated ($p < 0.05$). In the EGFL7-shRNA1 group, the mRNA and protein expressions of EGFL7, Notch1, Hes1, Bcl-2 and HEY1 were remarkably reduced, but Bax mRNA and protein expression was significantly increased ($p < 0.05$). When compared with the blank and NC groups, the mRNA and protein expressions of EGFL7 in the DAPT group showed no significant difference ($p > 0.05$), and Notch1, Hes1, Bcl-2 and HEY1 mRNA and protein expressions significantly decreased. In contrast, Bax protein and mRNA expression increased ($p < 0.05$). The result of the EGFL7-shRNA1 + DAPT group was the reverse of that in the EGFL7-OE group, with significantly increased mRNA and protein expression of EGFL7, Notch1, Hes1, Bcl-2 and HEY1 and notably decreased Bax mRNA and protein expression ($p < 0.05$).

Down-regulated EGFL7 inhibited A375 cell proliferation. We then investigated the effects of EGFL7 on the proliferation of A375 cells using MTT assay, and Figure 5 results showed there was no significant difference in cell proliferation ability at 24 hours. However, different proliferation ability was noted at 48, 72 and 96 h, but there was

no difference in the blank and NC groups. The proliferation ability of A375 cells in the EGFL7-OE group was significantly enhanced ($p < 0.05$), while the proliferation ability in the EGFL7-shRNA1, DAPT and EGFL7-shRNA1 + DAPT groups was reduced ($p < 0.05$); thus indicating that decreased EGFL7 expression inhibits the proliferation of CM A375 cells by suppressing the Notch signaling pathway.

EGFL7 repression facilitated A375 cell apoptosis by inactivating the Notch signaling pathway. Flow cytometry evaluated the regulatory effects of EGFL7 and Notch signaling pathway on CM A375 cell apoptosis. Figure 6, depicts no significant difference in cell apoptosis between the blank and NC groups ($p > 0.05$), but the apoptosis rate of the EGFL7-OE group was significantly decreased ($p < 0.05$). Nevertheless, the apoptosis rate in the EGFL7-shRNA1, DAPT and EGFL7-shRNA1 + DAPT groups increased significantly ($p < 0.05$). Therefore, EGFL7 repression promotes A375 cell apoptosis by inhibiting the Notch signaling pathway.

Decreased EGFL7 affected A375 cell cycle distribution by prolonging the G0/G1 phase and decreasing the S phase. PI single-staining flow cytometry measured the regulatory functions of EGFL7 and Notch signaling pathway on A375 cell cycle distribution. The results showed no significant




Figure 3. RT-qPCR and Western blot assay analyses demonstrated that EGFL7 and Notch related genes expressions increased in CM tissues compared with para-cancerous tissues. A) mRNA expression of EGFL7, Notch1, HES1, Bcl-2, and HEY1 were higher in the CM tissues than in the para-cancerous tissues in each group while Bax expression was decreased. B) protein expressions of EGFL7, Notch1, HES1, Bcl-2, and HEY1 were higher in the CM tissues than in the normal tissues in each group while Bax expression was decreased. C) protein bands in each group; Measurement data is presented as mean \pm standard deviation. The differences between two groups were analyzed using t-test; *, $p < 0.05$ compared with the para-cancerous tissues (n=65); CM, cutaneous melanoma (n=65); RT-qPCR, reverse transcription quantitative polymerase chain reaction; EGFL7, epidermal growth factor-like domain 7.




Figure 4. RT-qPCR and Western blot assay analyses suggested down-regulation of EGFL7 inhibited the Notch signaling pathway in the transfected A375 cells. A) mRNA expression of related genes expressions in each group; B) protein expression of EGFL7, Notch1, HES1, Bcl-2, HEY1 and Bax in each group; C) protein bands in each group; Data is by means \pm standard deviation from three independent experiments; statistical analysis in multiple groups was by one-way analysis of variance; the experiment was repeated three times; *, $p < 0.05$ compared with the blank and NC groups; NC, negative control.




Figure 5. Results of MTT assay showed that silencing of EGFL7 inhibited A375 cell proliferation. Data is means \pm standard deviation from three independent experiments; statistical analysis of multiple groups is by one-way analysis of variance; the experiment was repeated three times; *, $p < 0.05$ compared with the blank and NC groups; NC, negative control; MTT assay, 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide assay.

difference in cell cycle in the blank and NC groups ($p > 0.05$) but the G0/G1 phase was shortened and S phase was prolonged in the EGFL7-OE group. This established reduced apoptosis and accelerated proliferation. However, the G0/G1 phase was longer in the EGFL7-OE group and S phase was shortened in the EGFL7-shRNA1, DAPT and EGFL7-shRNA1 + DAPT groups, suggesting increased apoptosis and reduced proliferation ($p < 0.05$, Figure 7).

Down-regulated EGFL7 suppressed CM tumor growth.

Finally, the tumor formation in nude mice was assessed to determine the role of EGFL7 in melanoma. The results showed that no nude mice died in the experiments, but difference in tumor growth between the groups appeared within 3 days of inoculation. While no significant differences in tumor weight, tumor volume and MVD were found in the

blank and NC groups ($p > 0.05$), these were all increased in the EGFL7-OE group, while the EGFL7-shRNA1, DAPT and EGFL7-shRNA1 + DAPT groups were decreased ($p < 0.05$, Figure 8).

Discussion

Malignant melanoma is one of the most aggressive form of human skin cancer with a ten-year survival rate of approximately 24% for patients without distant metastases [18].

As a life-threatening malignancy with poor prognosis and a relatively high burden of mortality in advanced stages, the efficacy of current available therapeutic strategies of melanoma is limited, with a survival rate of less than 10% [19]. A recent study suggests that EGF expression is involved in altered human melanoma prognosis, and this indicates that tumor-derived EGF has a role in melanoma lymph node metastasis [20].

Herein, we established that down-regulated EGFL7 suppressed the occurrence and development of CM by




Figure 6. Flow cytometry analysis indicated that EGFL7 silencing improved apoptosis of A375 cells. A) apoptosis is slowed down in A375 cells transfected with EGFL7-shRNA1 or DAPT; B) apoptosis rate of A375 cells after transfection in each group. Data is means \pm standard deviation from three independent experiments; statistical analysis of multiple groups is by one-way analysis of variance; the experiment was repeated three times; *, $p < 0.05$ compared with the blank and NC groups; NC, negative control.




Figure 7. Comparison of the effect of EGFL7 and Notch related genes on cell cycle distribution in each group shown by flow cytometry. A) cell cycle distribution among six groups; B) cell cycle distribution at G0/G1, S and G2/M phases in different groups. Data is means \pm standard deviation from three independent experiments; statistical analysis of multiple groups is by one-way analysis of variance; the experiment was repeated three times; *, $p < 0.05$ compared with the blank and NC groups; NC, negative control.




Figure 8. Tumor xenografts in nude mice found that down-regulation of EGFL7 decreased the tumor weight, tumor volume and MVD. A) mice transfected with decreased EGFL7 and DAPT had the lowest tumor weight in 6 groups; B) mice transfected with decreased EGFL7 and DAPT had the lowest tumor volume in 6 experimental groups; C) mice transfected with decreased EGFL7 and DAPT had the lowest MVD in six groups. Data is means \pm standard deviation from three independent experiments (5 mice each group); statistical analysis in multiple groups was by one-way analysis of variance; the experiment was repeated three times; *, $p < 0.05$ compared with the blank and NC groups; NC, negative control; MVD, micro-vessel density.

inhibiting the Notch signaling pathway. Our study found high expression of EGFL7 in CM tissues, thus indicating that EGFL7 is a key conductor in CM. Moreover, various EGF polymorphisms have been reported to affect malignant melanoma susceptibility and prognosis [9].

The EGF gene is located on human chromosome 4q25. It spans approximately 110kb with 24 exons and 23 introns and its over-expression is an important step in melanoma pathogenesis [10]. For example, heparin-binding-EGF is a proven up-regulator in human melanoma, hepatocellular cancer, breast carcinoma, colon cancer, pancreatic cancer, glioma and glioblastoma through the cyclin D promoter [22]. EGF-8 promotes melanoma progression through coordinated Akt/twist signaling [21], and the secreted EGF-8 protein is also highly expressed in the vertical growth phase of melanoma [21]. Expression of the membrane bound tyrosine kinase EGF receptor is also elevated in advanced stages of melanoma, thus indicating it is a significant factor in EGF melanoma effects [23].

The EGFL7 protein is also known as Vascular Endothelial-statin (VE-statin) and it is secreted by both endothelial cells in normal tissues and in a variety of cancer cells [24]. It is a critical factor in carcinogenesis by affecting the development of vascular tube formation and is highly expressed in proliferating endothelial cells [12]. A previous study also found that EGFL7 activation resulted from the automatic dimerization of EGFRvIII triggered by EGFRwt in glioma tissue [25].

Additionally, we confirmed that decreased EGFL7 inhibited CM development through the suppression of the Notch signaling pathway which is commonly associated with tumorigenesis [26]. This pathway is widely implicated in

fundamental regulatory processes including cell proliferation and apoptosis [27]. It also facilitates cancerous cell growth in melanoma [28] and herein we established that Notch1 signaling is elevated in human melanoma specimens [29, 30].

Moreover, Notch1 accelerated melanoma development in a xenograft model by maintaining cell proliferation and protecting cells from stress-induced cell death [30], and it has proven a significant factor in melanoma progression by promoting VGP primary melanoma cells growth, [31]. Notch1 pathway activation is also widely acknowledged to promote cancer development and act as direct cell-cell communication in stem cell potential, cell fate determination and lineage commitment [32]. All Notch-related proteins are single-pass trans-membrane proteins with extracellular arrays of specific EGF repeats which mediate direct contact between ligand and receptor [33]. In addition, the extracellular portion of Notch has many EGF-like repeats followed by three cysteine-rich Notch/Lin12 repeats [34].

In conclusion, EGF is a member of the epidermal growth factor super-family; regulating cell differentiation, growth and proliferation [10]. The EGFL7 moiety's critical role in vascular development is closely related to melanoma tumor angiogenesis, and consequent vascular tube formation has an important function in carcinogenesis [11–13]. In addition, the milk fat globule EGF-8 promotes melanoma progression by coordinating AvB3 integrin signaling in the tumor micro-environment [21].

Our combined results define the roles of down-regulated EGFL7 in inhibiting CM development and finally, the EGFL7-mediated regulation of the Notch signaling pathway presents a novel mechanism for CM. EGFL7 could therefore be a novel therapeutic target in cutaneous melanoma.

Acknowledgments: We give our sincere appreciation to the reviewers for their helpful comments on this article.

References

- [1] GARBE C, PERIS K, HAUSCHILD A, SAIAG P, MID-
DLETON M et al. Diagnosis and treatment of melanoma.
European consensus-based interdisciplinary guideline -
Update 2016. *Eur J Cancer* 2016; 63: 201–217. <https://doi.org/10.1016/j.ejca.2016.05.005>
- [2] BETTUM IJ, GORAD SS, BARKOVSKAYA A, PET-
TERSEN S, MOESTUE SA et al. Metabolic reprogramming
supports the invasive phenotype in malignant melanoma.
Cancer Lett 2015; 366: 71–83. [https://doi.org/10.1016/j.can-
let.2015.06.006](https://doi.org/10.1016/j.can-
let.2015.06.006)
- [3] TESTA U, CASTELLI G, PELOSI E. Melanoma: Genetic
Abnormalities, Tumor Progression, Clonal Evolution and
Tumor Initiating Cells. *Med Sci (Basel)* 2017; 5. <https://doi.org/10.3390/medsci5040028>
- [4] TODD SP, DRISCOLL MS. Prognosis for women diagnosed
with melanoma during, before, or after pregnancy: Weighing
the evidence. *Int J Womens Dermatol* 2017; 3: 26–29. [https://
doi.org/10.1016/j.ijwd.2016.12.004](https://
doi.org/10.1016/j.ijwd.2016.12.004)
- [5] GORDON D, GILLGREN P, ELORANTA S, OLSSON H,
GORDON M et al. Time trends in incidence of cutaneous
melanoma by detailed anatomical location and patterns of
ultraviolet radiation exposure: a retrospective population-
based study. *Melanoma Res* 2015; 25: 348–356. <https://doi.org/10.1097/CMR.0000000000000170>
- [6] OKANO Y, SATOH T, HORIGUCHI K, TOYODA M,
OSAKI A et al. Nivolumab-induced hypophysitis in a pa-
tient with advanced malignant melanoma. *Endocr J* 2016;
63: 905–912. <https://doi.org/10.1507/endocrj.EJ16-0161>
- [7] ALEGRE E, ZUBIRI L, PEREZ-GRACIA JL, GONZALEZ-
CAO M, SORIA L et al. Circulating melanoma exosomes as
diagnostic and prognosis biomarkers. *Clin Chim Acta* 2016;
454: 28–32. <https://doi.org/10.1016/j.cca.2015.12.031>
- [8] MOHR P, ASCIERTO P, ARANCE A, MCARTHUR G,
HERNAEZ A et al. Real-world treatment patterns and out-
comes among metastatic cutaneous melanoma patients
treated with ipilimumab. *J Eur Acad Dermatol Venereol*
2018; 32: 962–971. <https://doi.org/10.1111/jdv.14633>
- [9] WANG XH, LONG ZW. Correlations of EGF G1380A,
bFGF C754G and VEGF T460C polymorphisms with ma-
lignant melanoma susceptibility and prognosis: A case-con-
trol study. *Gene* 2017; 617: 44–53. [https://doi.org/10.1016/j.
gene.2017.02.023](https://doi.org/10.1016/j.
gene.2017.02.023)
- [10] WU D, WU Y, ZHANG X, CONG P, LV X. Lack of associa-
tion between EGF +61A>G polymorphism and melanoma
susceptibility in Caucasians: a HuGE review and meta-
analysis. *Gene* 2013; 515: 359–366. [https://doi.org/10.1016/j.
gene.2012.11.014](https://doi.org/10.1016/j.
gene.2012.11.014)
- [11] NICHOL D, STUHLMANN H. EGFL7: a unique angio-
genic signaling factor in vascular development and dis-
ease. *Blood* 2012; 119: 1345–1352. [https://doi.org/10.1182/
blood-2011-10-322446](https://doi.org/10.1182/
blood-2011-10-322446)
- [12] DENG QJ, XIE LQ, LI H. Overexpressed MALAT1 promotes
invasion and metastasis of gastric cancer cells via increas-
ing EGFL7 expression. *Life Sci* 2016; 157: 38–44. <https://doi.org/10.1016/j.lfs.2016.05.041>
- [13] HUH SJ, CHUNG CY, SHARMA A, ROBERTSON GP.
Macrophage inhibitory cytokine-1 regulates melanoma
vascular development. *Am J Pathol* 2010; 176: 2948–2957.
<https://doi.org/10.2353/ajpath.2010.090963>
- [14] ZHANG JB, QIN HY, WANG L, LIANG L, ZHAO XC et al.
Overexpression of Notch ligand DLL1 in B16 melanoma
cells leads to reduced tumor growth due to attenuated vas-
cularization. *Cancer Lett* 2011; 309: 220–227. <https://doi.org/10.1016/j.canlet.2011.06.008>
- [15] ANDERSSON ER, SANDBERG R, LENDAHL U. Notch
signaling: simplicity in design, versatility in function. *De-
velopment* 2011; 138: 3593–3612. [https://doi.org/10.1242/
dev.063610](https://doi.org/10.1242/
dev.063610)
- [16] SALEM A, MRAD K, DRISS M, HAMZA R, MNIF N. [In-
tracystic papillary carcinoma of the breast]. *J Radiol* 2009;
90: 515–518
- [17] YANG HF, DU Y, NI JX, ZHOU XP, LI JD et al. Perfu-
sion computed tomography evaluation of angiogenesis in
liver cancer. *Eur Radiol* 2010; 20: 1424–1430. <https://doi.org/10.1007/s00330-009-1693-y>
- [18] WEBER CE, LUO C, HOTZ-WAGENBLATT A, GARDY-
AN A, KORDASS T et al. miR-339-3p Is a Tumor Suppressor
in Melanoma. *Cancer Res* 2016; 76: 3562–3571. <https://doi.org/10.1158/0008-5472.CAN-15-2932>
- [19] MIRZAEI H, GHOLAMIN S, SHAHIDSALES S, SAHEB-
KAR A, JAAFARI MR et al. MicroRNAs as potential diag-
nostic and prognostic biomarkers in melanoma. *Eur J Cancer*
2016; 53: 25–32. <https://doi.org/10.1016/j.ejca.2015.10.009>
- [20] BRACHER A, CARDONA AS, TAUBER S, FINK AM,
STEINER A et al. Epidermal growth factor facilitates mela-
noma lymph node metastasis by influencing tumor lym-
phangiogenesis. *J Invest Dermatol* 2013; 133: 230–238.
<https://doi.org/10.1038/jid.2012.272>
- [21] JINUSHI M, NAKAZAKI Y, CARRASCO DR, DRAGAN-
OV D, SOUDERS N et al. Milk fat globule EGF-8 promotes
melanoma progression through coordinated Akt and twist
signaling in the tumor microenvironment. *Cancer Res* 2008;
68: 8889–8898. [https://doi.org/10.1158/0008-5472.CAN-08-
2147](https://doi.org/10.1158/0008-5472.CAN-08-
2147)
- [22] ONGUSAHA PP, KWAK JC, ZWIBLE AJ, MACIP S, HI-
GASHIYAMA S et al. HB-EGF is a potent inducer of tumor
growth and angiogenesis. *Cancer Res* 2004; 64: 5283–5290.
<https://doi.org/10.1158/0008-5472.CAN-04-0925>
- [23] OKAMOTO I, ROKA F, KROGLER J, ENDLER G,
KAUFMANN S et al. The EGF A61G polymorphism is as-
sociated with disease-free period and survival in malignant
melanoma. *J Invest Dermatol* 2006; 126: 2242–2246. [https://
doi.org/10.1038/sj.jid.5700377](https://
doi.org/10.1038/sj.jid.5700377)
- [24] DELFORTRIE S, PINTE S, MATTOT V, SAMSON C, VIL-
LAIN G et al. Egfl7 promotes tumor escape from immunity
by repressing endothelial cell activation. *Cancer Res* 2011 1;
71: 7176–7186. [https://doi.org/10.1158/0008-5472.CAN-11-
1301](https://doi.org/10.1158/0008-5472.CAN-11-
1301)

- [25] WANG FY, KANG CS, WANG-GOU SY, HUANG CH, FENG CY et al. EGFL7 is an intercellular EGFR signal messenger that plays an oncogenic role in glioma. *Cancer Lett* 2017; 384: 9–18. <https://doi.org/10.1016/j.canlet.2016.10.009>
- [26] KIMURA K, SATOH K, KANNO A, HAMADA S, HIROTA M et al. Activation of Notch signaling in tumorigenesis of experimental pancreatic cancer induced by dimethylbenzanthracene in mice. *Cancer Sci* 2007; 98: 155–162.
- [27] FORTINI ME. Notch signaling: the core pathway and its posttranslational regulation. *Dev Cell* 2009; 16: 633–647. <https://doi.org/10.1016/j.devcel.2009.03.010>
- [28] Garraway LA. A Notch for noncoding RNA in melanoma. *N Engl J Med* 2014; 370: 1950–1951. <https://doi.org/10.1056/NEJMcibr1402173>
- [29] BALINT K, XIAO M, PINNIX CC, SOMA A, VERES I et al. Activation of Notch1 signaling is required for beta-catenin-mediated human primary melanoma progression. *J Clin Invest* 2005; 115: 3166–3176. <https://doi.org/10.1172/JCI25001>
- [30] BEDOGNI B, WARNEKE JA, NICKOLOFF BJ, GIACCIA AJ, POWELL MB. Notch1 is an effector of Akt and hypoxia in melanoma development. *J Clin Invest* 2008; 118: 3660–3670. <https://doi.org/10.1172/JCI36157>
- [31] LIU ZJ, XIAO M, BALINT K, SMALLEY KS, BRAFFORD P et al. Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression. *Cancer Res* 2006; 66: 4182–4190. <https://doi.org/10.1158/0008-5472.CAN-05-3589>
- [32] DOTTO GP. Notch tumor suppressor function. *Oncogene* 2008; 27: 5115–5123. <https://doi.org/10.1038/onc.2008.225>
- [33] LAI EC. Notch signaling: control of cell communication and cell fate. *Development* 2004; 131: 965–973. <https://doi.org/10.1242/dev.01074>
- [34] RADTKE F, RAJ K. The role of Notch in tumorigenesis: oncogene or tumour suppressor? *Nat Rev Cancer* 2003; 3: 756–767. <https://doi.org/10.1038/nrc1186>